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Abstract
Background
CD73 dephosphorylates adenosine monophosphate to adenosine that is an anti-inflamma-
tory molecule inhibiting immune activation and vascular leakage. Therefore, CD73 could be
an interesting mediator both in sepsis and acute kidney injury (AKI). We aimed to explore
the soluble CD73 (sCD73) levels and their evolution in critically ill patients with severe sep-
sis and, second, to scrutinize the potential association of sCD73 levels with AKI and 90-day
mortality.
Methods
This was a post-hoc laboratory analysis of the prospective, observational FINNAKI study
conducted in 17 Finnish ICU during 5 months in 2011–2012. Plasma samples of 588
patients admitted with severe sepsis/shock or with developing severe sepsis were analyzed
at 0h (ICU admission) and 24h, and additionally, on day 3 or day 5 from a subset of the
patients.
Results
The median [IQR] sCD73 levels at 0h were 5.11 [3.29–8.28] ng/mL and they decreased sig-
nificantly from 0h to 4.14 [2.88–7.11] ng/mL at 24h, P<0.001. From 24h to Day 3 (n = 132)
the sCD73 levels rose to 5.18 [2.98–8.83] ng/mL (P = 0.373) and from 24h to Day 5 (n =
224) to 5.52 [3.57–8.90] ng/mL (P<0.001). Patients with AKI had higher sCD73 values at
0h and at 24h compared to those without AKI. Non-survivors with severe sepsis, but not
with septic shock, had higher CD73 levels at each time-point compared to survivors. After
multivariable adjustments, sCD73 levels at 0h associated independently neither with the
development of AKI nor 90-day mortality.
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Conclusions
Compared to normal population, the sCD73 levels were generally low at 0h, showed a
decrease to 24h, and later an increase by day 5. The sCD73 levels do not seem useful in
predicting the development of AKI or 90-day mortality among patients with severe sepsis or
shock.
Background
Severe sepsis is diagnosed up to a third of patients treated in intensive care units (ICUs) [1, 2].
Multiple organ dysfunction (MODS) frequently complicates the course of illness in septic
patients and acute kidney injury (AKI) is especially frequent among them [2]. Although the
mortality in severe sepsis has showed a decreasing trend [3], it still remains high being 35%
within 90-days from ICU admission [2].
The complex pathophysiology of severe sepsis involves both pro-inflammatory reactions to
eliminate the invading pathogens and anti-inflammatory responses to limit local and systemic
tissue injury [1]. CD73 is an enzyme that dephosphorylates adenosinemonophosphate to
adenosine, which is a potent anti-inflammatorymolecule inhibiting immune activation and
vascular leakage [4]. Inhibition of degradation of adenosine decreased leukocyte rolling and
adhesion and microvascular dysfunction, and associated with improved survival of septic mice
[5]. In further animal models, these effects of adenosine have been shown to occur via CD73
dependent pathways suggesting that CD73-derived adenosinemight be beneficial in sepsis [4].
Additionally, CD73 has been suggested to be protective in hypoxia [6] that frequently occurs in
the setting of septic shock and MODS. Inflammation can also trigger dysfunction of vascular
endothelium increasing tissue edema [7] and CD73 has a key role in re-sealing the endothelial
barrier after leukocyte transmigration [6].
CD73 is especially abundant on the cell surfaces in the kidneys [8]. CD73 deficient mice
present with proteinuria and deteriorated renal function even in the absence of acute stress fac-
tors [9]. Besides alleviating kidney injury in septic mice [4], CD73 has been identified as an
endogenous protector from ischemia in the kidneys [8]. In the setting of experimental ische-
mia-reperfusion injury, the volatile anesthetic isoflurane has been shown to transiently increase
the release of active CD73 from endothelial microparticles and to protect from AKI by attenu-
ating the endothelial inflammation and apoptosis [10, 11].
In humans, patients with more severe acute pancreatitis had decreased levels of plasma
soluble CD73 (sCD73), and the activity of soluble form of CD73 showed prognostic value in
predicting the development of severe acute pancreatitis [12]. Furthermore, interferon-beta
treatment that up-regulates CD73, was associated with a reduction in mortality among patients
with acute respiratory distress syndrome (ARDS), possibly by decreasing the pulmonary
capillary permeability [13]. Capillary leak is a major problem among patients with sepsis [7],
and thus, alleviating this phenomenon would be likely to improve the treatment of septic
patients.
Therefore, CD73 is an interesting mediator both in sepsis and AKI and a potential target of
therapeutic interventions. However, the sCD73 levels among critically ill patients with severe
sepsis or AKI are currently unknown.We hypothesized that in severe sepsis and septic shock,
the sCD73 concentrations would be decreased–onepotential underlyingmechanism being
increased degradation. Thus, we decided to explore the sCD73 levels and their evolution in crit-
ically ill patients with severe sepsis. Moreover, we aimed to scrutinize the potential association
of sCD73 levels with AKI and 90-day mortality.
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Methods
This was a post-hoc laboratory study of the prospective, observational Finnish Acute Kidney
Injury (FINNAKI) study [14] conducted in 17 Finnish intensive care units (ICUs) between
September 1, 2011 and February 1, 2012. The Ethics Committee of the Department of Surgery
at the Helsinki University Hospital gave nationwide approval for the study protocol that
included the analysis of inflammatory and anti-inflammatory biomarkers and thus covered the
current analysis. The Ethics Committee approved the use of deferred consent with written,
informed consent obtained as soon as possible. Patients enrolled in the study were critically ill,
and thus, mostly unable to consent themselves at the time of ICU admission, and contacting
patient’s next of kin without delays is not always possible. Consequently, the deferred consent
strategy was used to avoid delays in enrolling patients and to allow collecting samples at ICU
admission. If the patient was not able to consent due to his/her critical illness, patient’s next of
kin was approached as soon as possible to obtain written, informed consent. Laboratory sam-
ples were stored and analyzed only if a written, informed consent was obtained from the
patient or his/her next of kin. The Finnish National Institute of Health approved data collec-
tion from the medical records of deceased patients if informed consent could not be obtained
to avoid bias in the primary endpoint of the FINNAKI study, namely the incidence and out-
come of AKI [14]. The current laboratory sub-analysis includes only patients who gave or
whose next of kin gave a written, informed consent. The study was conducted according to the
Declaration of Helsinki.
We enrolled all patients with an emergency admission of any duration or an elective post-
surgical admission expected to last over 24h in the study. Patients were excluded if they 1) had
end-stage renal disease requiringmaintenance dialysis, 2) were organ donors, 3) received inter-
mediate care, 4) had received renal replacement therapy (RRT) while enrolled in the study dur-
ing a previous ICU admission, 5) were transferred from another ICU where the data collection
for the study was fulfilled, or 6) were not permanently living in Finland or were unable to give
consent due to insufficient language skills. In the current analysis we focused on septic patients
and, thus, included patients with blood samples at the ICU admission and at 24h and who ful-
filled criteria for severe sepsis/shock [15] within 5 days in ICU [2] (Fig 1).
Data collection
We recorded patient characteristics, physiological and laboratory data, severity scores, given
ICU treatment, diagnoses, and pre-existing comorbidities using case report forms and the ICU
data management system via the Finnish Intensive Care Consortiumdatabase. Pre-existing
chronic comorbidities were deemed present, if mentioned in the patient records. Data were
recorded until day 5 if still in ICU. Statistics Finland provided data on survival status at 90
days.
Definitions
Severe sepsis was defined according to the American College of Chest Physicians/Society of
Critical Care Medicine (ACCP/SCCM) definition [15]. Attending clinicians screened the
patients for the presence of severe sepsis at the ICU admission and thereafter daily until the
diagnostic criteria were fulfilled.We defined the onset of septic shock according to the time of
vasopressor initiation (considering norepinephrine, dopamine, or epinephrine).We used Kid-
ney Disease; Improving Global Outcomes (KDIGO) criteria [16] to screen and stage acute kid-
ney injury (AKI) considering both creatinine (measured daily) and urine output (recorded
hourly) criteria. Pre-existing chronic comorbidities were defined positive, if mentioned in the
patient records. In terms to study the ability of the biomarker to predict AKI, we excluded
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patients admitted with AKI or AKI diagnosedwithin the first 12h in the ICU for this particular
analysis [2].
Samples
No previous data on sCD73 levels in septic patients existed to allow a formal sample size calcu-
lation. Based on previous studies on novel biomarkers in critically ill septic patients [17, 18],
and the known incidence of AKI and 90-day mortality in the FINNAKI population, we decided
to study a convenience sample of 600 patients to include a sufficient amount of patients with
the main endpoints, namely development of AKI and 90-day mortality [2]. Samples from 12
patients could not be located, and thus, we analyzed plasma samples drawn immediately after
ICU admission (0h) and at 24h from 588 consecutive patients with both samples available.
Additionally, for patients enrolled before Dec 1, 2011, the study protocol included blood sam-
ples drawn on day 3 and on day 5 if still in ICU. Thus, we analyzed samples from patients who
had samples available from day 3 or 5 preferring the sample taken on day 5 if both were avail-
able. Plasma samples were collected in EDTA tubes, centrifuged, and transferred into plastic
tubes and frozen. Samples were kept in -80 degrees until analyzed in August 2015.
Fig 1. Study flow chart ICU; intensive care unit.
doi:10.1371/journal.pone.0164420.g001
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CD73 assays
For the analysis of sCD73 in plasma a sandwich ELISAwas performed as previously described
[12] with a fewmodifications. The validation of the newmethod (DELFIA) is described in
detail in the S1 Text Material, Supplementary Methods. To verify that sCD73 levels obtained
by DELFIA were indicative of CD73 activity 42 randomly selected patient samples were mea-
sured also for CD73 enzyme activity as previously described [19].
Statistical analyses
We report the non-normally distributed continuous data as median with interquartile range
(IQR) and compared it using Mann-Whitney U-test or Kruskal-Wallis test (for comparisons of
groups). We report categorical data with count and percentage, and compared it using Fisher’s
exact test or Chi-square test where appropriate. Data from two different time-points was com-
pared usingWilcoxon’s signed rank test. We studied correlations of two continuous variables
with Spearman’s rho. We assessed the predictive ability of the biomarker by calculating the
area under the receiver-operator characteristic curve (AUC). Additionally, we performed uni-
variate modeling for the development of AKI and 90-day mortality, and entered factors with a
P-value less than 0.20 in univariate models in multivariable logistic regression to study the
independent association of sCD73 levels with these two outcomes. We considered a two-sided
p-value less than 0.05 as significant and did not correct for multiple comparisons. All analyses
were conducted in SPSS Statistics 20.0 for Mac (IBM, Armonk, NY).
Results
Validation of the new CD73 assay and correlation of CD73 activity with
sCD73
We found the DELFIA assay for the detection of sCD73 to be reliable, but the absolute values
obtained by the DELFIA method were lower than that detected by the ELISAmethod [12] and
therefore cannot be directly compared. However, in a population cohort analyzed with the
DELFIA the median [IQR] values for men (n = 1194) were 6.28 ng/ml [5.25–7.66] and for
women (n = 1243) 6.46 ng/ml [5.4–8.01]. Also, the sCD73 protein concentration obtained with
DELFIA correlated with the CD73 activity (Spearman’s rho 0.838, P<0.001) in randomly
selected 42 patient samples. The median [IQR] CD73 activity among these 42 patients was 730
[342–1416] nmol/mL/h.
Study population and sCD73 levels
Samples from 588 consecutive patients were analyzed (study flow chart with exclusions pre-
sented as Fig 1). Patients included in the analysis were otherwise representative of the overall
cohort with severe sepsis in the FINNAKI study (comparison of patient characteristics pre-
sented in the S1 Table), but patients who were not included had higher disease severity, shorter
ICU stay, and higher 90-day mortality.
Of the 588 patients, 190 (32.3%) were admitted with septic shock, 300 (51.0%) were admit-
ted with severe sepsis and 179 (59.7%) of them developed septic shock within a median [IQR]
of 2.9 [1.7–9.2] hours. Of the 98 (16.7%) patients admitted without fulfilling the criteria for
severe sepsis/septic shock, 60 (61.2%) were diagnosedwith septic shock after a median [IQR]
of 5.4 [2.4–23.7] hours.
Among all patients, the median [IQR] sCD73 levels at 0h were 5.11 [3.29–8.28] ng/mL.
Table 1 summarizes the patient characteristics grouped in tertiles according to the sCD73 levels
at ICU admission. Patients with pre-existing chronic liver failure (n = 31) had higher sCD73
Soluble CD73 in Septic Critically Ill Patients
PLOS ONE | DOI:10.1371/journal.pone.0164420 October 12, 2016 5 / 14
levels at 0h compared to those without (n = 551), median [IQR] 7.54 [4.08–13.48] vs. 5.04
[3.26–8.20] ng/mL, P = 0.014. In comparisons according to the presence of other pre-existing
comorbidities (hypertension, chronic obstructive pulmonary disease, arteriosclerosis, diabetes,
systolic heart failure, chronic kidney disease, or rheumatoid disease), no differences in sCD73
levels at 0h existed (data not shown).
The sCD73 levels decreased significantly from 5.11 [3.29–8.28] ng/mL at 0h to 4.14 [2.88–
7.11] ng/mL at 24h, P<0.001. From measurement at 24h to Day 3 (n = 132) the sCD73 levels
rose to 5.18 [2.98–8.83] ng/mL (p = 0.373) and from 24h to Day 5 (n = 224) 5.52 [3.57–8.90]
ng/mL (P<0.001).When patients were grouped in tertiles according to the change in sCD73
values from 0 to 24h, patients in the the lowest tertile (median [IQR] change -3.02 [-5.73–-2.28]
ng/ml) had higher lactate and SOFA scores on day 1 compared to those in the highest tertile
(median [IQR] change 0.26 [-0.05–1.17] ng/ml) (S2 Table).
Severity of sepsis and sCD73
Fig 2 presents sCD73 levels in all time points according to the severity of sepsis. Patients admit-
ted without severe sepsis/shock had significantly higher sCD73 levels compared to those
Table 1. Patient characteristics in tertiles according to the sCD73 level at the ICU admission.
Low Middle High P valuea
sCD73 –ng/ml 2.83 [2.26–3.30] 5.11 [4.41–6.02] 11.54 [8.25–18.20]
Age -years 68 [56–77] 63 [48–74] 65 [55–74] 0.121
Male sex 124/196 (63.3%) 126/196 (64.3%) 133/196 (67.9%) 0.395
Hypertension 105/195 (53.8%) 89/195 (45.6%) 102/194 (52.6%) 0.839
Diabetes 46/196 (23.5%) 41/196 (20.9%) 61/196 (31.1%) 0.112
Chronic obstructive pulmonary disease 26/194 (13.4%) 23/193 (11.9%) 21/193 (10.9%) 0.534
Universal arteriosclerosis 29/195 (14.9%) 23/194 (11.9%) 32/193 (16.6%) 0.677
Chronic liver failure 6/195 (3.1%) 8/192 (4.2%) 17/195 (8.7%) 0.030
Chronic kidney disease 13/194 (6.7%) 9/196 (4.6%) 19/195 (9.7%) 0.356
Number of pre-existing comorbidities (0–8) 1 [0–2] 1 [0–2] 1 [0–2] 0.145
Operative admission 72/196 (36.7%) 40/196 (20.4%) 35/196 (17.9%) <0.001
Mechanical ventilation in ICU 135/196 (68.9%) 138/196 (70.4%) 139/196 (70.9%) 0.741
SAPS II score within 24h (0–163) 40 [32–51] 42 [34–52] 41 [34–56] 0.032
SAPS II score without age points within 24h (0–145) 27 [32–51] 42 [34–52] 41 [34–56] 0.002
SOFA score, first 24h (0–24) 7 [6–10] 8 [6–10] 9 [7–11] <0.001
Lactate, first in ICUb (mmol/l) 1.5 [1.0–2.5] 1.7 [1.0–2.6] 1.8 [1.1–3.6] 0.027
Fluid balance, cumulative ad day2c -mL 2225 [–29–4292] 1458 [–402–3984] 2230 [–197–4992] 0.477
Septic shock 152/196 (77.6%) 139/196 (70.9%) 138/196 (70.4%) 0.134
Acute kidney injury 90/196 (45.9%) 105/196 (53.6%) 120/196 (61.2%) <0.003
-stage 1 43 (21.95) 38 (19.4%) 46 (23.5%)
-stage 2 18 (9.2%) 26 (13.3%) 22 (11.2%)
-stage 3 29 (14.8%) 41 (20.9%) 52 (26.5%)
Renal replacement therapy 18/196 (9.2%) 29/196 (14.8%) 41/196 (20.9%) 0.002
Length of ICU stay (days) 4.5 [2.6–8.2] 4.6 [2.7–7.1] 5.0 [3.0–8.7] 0.199
Dead by day 90 45/196 (23.0%) 54/196 (27.6%) 65/196 (33.2%) 0.032
Data presented as median [IQR] or with count/total number and percentage.
aP-values are from comparison between the lowest and highest tertile.
b Data missing for 24, 21, and 17 patients
c Data missing for 19, 19, and 13 patients
SAPS; Simplified Acute Physiology Score, SOFA; Sequential Organ Failure Assessment
doi:10.1371/journal.pone.0164420.t001
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admitted with severe sepsis or shock. Patients with severe sepsis did not differ from those with
septic shock at 0h, but at 24h and on day 3 their sCD73 levels were higher. sCD73 level at 0h
did not predict the development of septic shock among those 398 patients admitted without
shock, the AUC was 0.47 (95% CI 0.42–0.53). The sCD73 levels at different time-points did not
correlate with the severity of sepsis at that time-point (intraclass correlation -0.492; 95% CI
-0.493–-0.491, P>0.999).
Acute kidney injury and sCD73
Patients with AKI diagnosed until day 5 in the ICU had higher sCD73 values at 0h and at 24h
compared to those without AKI (Table 2). When patients admitted with AKI (AKI diagnosis
<12h from ICU admission, n = 179) were excluded, the sCD73 levels at 0h but not at 24h were
significantly higher. After adjusting for confounders, sCD73 level at 0h categorized in tertiles
was not significantly associated with an increased risk of development of AKI Table 3. Patients
who eventually received RRT had higher CD73 levels at 0h (when not yet in RRT), P = 0.004,
but not in other time-points (P = 0.072 at 24h, 0.171 on day 3, and 0.343 on day 5).
Fig 2. Box-plots presenting sCD73 levels according to the severity of sepsis at the time of sampling. The
figure is truncated at level 30 ng/mL level excluding 51 (3.3%) of the cases (range in values 0.47 to 220.59 ng/mL).
ICU; intensive care unit. Comparisons: ICU admission: severe sepsis (n = 300) vs. septic shock (n = 190)
P = 0.158; no sepsis (n = 98) vs. severe sepsis, P = 0.08; no sepsis vs. septic shock P = 0.011, across all three
groups P = 0.031. 24H: severe sepsis (n = 172) vs. septic shock (n = 404) P = 0.039; no sepsis (n = 12) vs. severe
sepsis, p = 0.980; no sepsis vs. septic shock P = 0.593; across all three groups P = 0.196. Day 3: severe sepsis
(n = 34) vs. septic shock (n = 98) P = 0.014. Day 5: severe sepsis (n = 44) vs. septic shock (n = 180) P = 0.086.
doi:10.1371/journal.pone.0164420.g002
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90-day mortality and sCD73
Of the 588 patients, 164 (27.9%; 95% CI from 24.3% to 31.5%) were dead by day 90. The non-
survivors had significantly higher sCD73 levels both at 0h and at 24h (Table 4). The difference
remained significant, when patients with AKI were excluded.When patients with severe sepsis
and septic shock were analyzed separately, the difference between survivors and non-survivors
was seen only among those with severe sepsis. After adjusting for several confounders, sCD73
level at 0h was not associated with an increased risk for 90-day mortality (Table 5). Patients did
not differ in terms of 90-day mortality when compared in groups according to the change in
sCD73 levels between 0 and 24h (Additional File Table 2).
Table 2. Soluble CD73 concentrations (ng/mL) according to the presence/development of acute kidney injury (AKI).
All AKI (n = 315) No AKI (n = 273) Pa AKI >12h from ICU admission (n = 136) P-valueb
-0h 5.67 [3.44–9.30] 4.55 [3.20–7.29] 0.004 5.48 [3.56–8.51] 0.040
-24h 4.50 [2.95–7.67] 3.91 [2.80–6.62] 0.044 4.28 [3.06–7.44] 0.157
-Decrease from 0h to 24h 0.86 [0.11–2.27] 0.67 [0.04–1.69] 0.106 0.79 [0.15–2.29] 0.121
Day 3c 5.47 [2.95–9.52] 4.94 [2.99–7.25] 0.484 4.12 [2.42–7.68] 0.580
Day 5d 5.71 [3.57–9.07] 5.23 [3.57–8.32] 0.618 5.64 [3.76–9.14] 0.484
a Comparison between all AKI and non-AKI patients
b Comparison between AKI>12h and non-AKI patients
c Number of patients: All AKI 75, No AKI 57, AKI >12h 25
d Number of patients: All AKI 123, No AKI 101, AKI >12h 61
doi:10.1371/journal.pone.0164420.t002
Table 3. Univariate and multivariable logistic regression models for the development of AKI.
Univariate OR (95% CI) P-value Multivariate OR (95% CI) P-value
sCD73 0h –ng/ml 1.01 (0.99–1.03) 0.266
sCD73 0h –categorized in tertiles 1.30 (1.00–1.68) 0.046 1.32 (0.98–1.78) 0.070
Age 1.02 (1.01–1.03) 0.004 1.02 (1.00–1.03) 0.025
Male gender 0.89 (0.58–1.37) 0.590
Hypertension 1.36 (0.90–2.06) 0.141 1.05 (0.63–1.74) 0.868
Diabetes 1.56 (0.97–2.50) 0.067 1.19 (0.67–2.10) 0.560
Chronic obstructive pulmonary disease 0.52 (0.26–1.06) 0.070 0.43 (0.20–0.93) 0.032
Universal arteriosclerosis 0.92 (0.50–1.70) 0.788
Chronic liver failure 1.00 (0.40–2.55) 0.993
Chronic kidney disease 4.42 (1.84–10.60) 0.001 4.11 (1.50–11.23) 0.006
Operative admission 1.41 (0.89–2.24) 0.145 1.01 (0.58–1.77) 0.970
Vasoactive drugs on day 1 2.38 (1.49–3.82) <0.001 0.77 (0.36–1.62) 0.485
Mechanical ventilation in ICU 1.85 (1.14–2.99) 0.013 1.56 (0.85–2.84) 0.149
SAPS II score without age and renal points within 24h 1.29 (1.14–1.46) <0.001 0.99 (0.97–1.01) 0.382
Lactate, first in ICUb (mmol/l)a 1.29 (1.24–1.46) <0.001 1.21 (1.07–1.37) 0.002
Fluid balance, cumulative ad day2c –mL–categorized quintilesb 1.47 (1.20–1.81) <0.001 1.24 (0.99–1.55) 0.066
Septic shock 2.82 (1.71–4.64) <0.001 3.02 (1.38–6.59) 0.006
ICU; Intensive care unit, CI; confidence interval, OR; odds ratio, SAPS; Simplified Acute Physiology Score. Number of patients included in the multivariable
model was 402 (0f 409). Hosmer-Lemeshow Chi-Square 9.12, P = 0.332.
a42 missing values imputed with the median value for the multivariable model
b38 missing values imputed with the median value for the multivariable model
doi:10.1371/journal.pone.0164420.t003
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Table 4. Soluble CD73 concentrations (ng/mL) according to the 90-day survival.
N 90-day survivors N 90-day non-survivors P-value
All patients
-0h 424 4.87 [3.21–7.93] 164 5.73 [3.65–10.25] 0.018
-24h 424 3.96 [2.83–6.71] 164 4.80 [3.07–8.73] 0.013
-Day 3 97 4.98 [2.77–7.86] 35 6.05 [3.95–10.43] 0.115
-Day 5 151 5.30 [3.49–8.88] 73 5.80 [3.67–8.98] 0.995
Severe sepsis
-0h 121 4.91 [3.31–7.31] 38 8.15 [4.59–15.00] 0.001
-24h 121 4.09 [2.88–7.02] 38 6.69 [3.77–11.71] 0.005
-Day 3 25 5.74 [3.04–9.75] 8 9.34 [6.41–32.94] 0.026
-Day 5 30 7.05 [4.09–9.64] 14 6.41 [4.02–11.00] >0.999
Septic shock
-0h 303 4.83 [3.12–8.12] 126 5.15 [3.30–8.83] 0.330
-24h 303 3.90 [2.80–6.68] 126 4.37 [2.87–8.05] 0.168
-Day 3 72 4.82 [2.62–7.23] 27 4.62 [3.20–9.17] 0.535
-Day 5 121 5.14 [3.43–8.98] 59 5.57 [3.66–8.44] 0.971
Patients without acute kidney injury
-0h 215 4.31 [3.01–6.89] 58 5.30 [3.60–11.13] 0.009
-24h 215 3.77 [2.76–6.30] 58 4.43 [3.12–9.62] 0.018
-Day 3 49 4.84 [2.85–6.61] 8 7.68 [4.29–24.43] 0.073
-Day 5 69 4.61 [3.24–7.97] 32 6.37 [4.21–10.62] 0.049
Data presented as median [IQR]
doi:10.1371/journal.pone.0164420.t004
Table 5. Univariate and multivariable logistic regression models for 90-day mortality.
Univariate OR (95% CI) P-value Multivariate OR (95% CI) P-value
sCD73 0h –ng/ml 1.01 (0.99–1.02) 0.331
sCD73 0h –categorized in tertiles 1.29 (1.03–1.61) 0.025 1.19 (0.92–1.53) 0.177
Age 1.04 (1.03–1.05) <0.001 1.05 (1.03–1.07) <0.001
Male gender 1.26 (0.86–1.86) 0.234
Hypertension 1.36 (0.94–1.95) 0.101 0.90 (0.58–1.38) 0.623
Diabetes 0.86 (0.56–1.31) 0.487
Chronic obstructive pulmonary disease 1.13 (0.66–1.96) 0.655
Universal arteriosclerosis 1.36 (0.83–1.23) 0.225
Chronic liver failure 2.96 (1.43–6.14) 0.004 4.31 (1.86–9.99) 0.001
Chronic kidney disease 1.95 (1.02–3.73) 0.044 1.67 (0.82–3.42) 0.160
Operative admission 0.59 (0.38–0.92) 0.020 0.49 (0.28–0.83) 0.008
Vasoactive drugs on day 1 1.28 (0.85–1.93) 0.234
Mechanical ventilation in ICU 1.84 (1.20–2.81) 0.005 1.43 (0.84–2.41) 0.186
SAPS II score without age and renal points within 24h 1.04 (1.03–1.06) <0.001 1.04 (1.02–1.06) <0.001
Lactate, first in ICUb (mmol/l)a 1.05 (0.99–1.12) 0.108 0.97 (0.90–1.05) 0.513
Fluid balance, cumulative ad day2c –mL–categorized in kvintilesb 1.28 (1.08–1.52) 0.005 1.20 (0.99–1.46) 0.060
Septic shock 1.32 (0.87–2.01) 0.190 1.00 (0.61–1.64) 0.993
ICU; Intensive care unit, CI; confidence interval, OR; odds ratio, SAPS; Simplified Acute Physiology Score. Number of patients included in the multivariable
model was 573. Hosmer-Lemeshow Chi-Square 10.93, P = 0.206.
a 62 missing values imputed with the median value for the multivariable model
b 51 missing values imputed with the median value for the multivariable model
doi:10.1371/journal.pone.0164420.t005
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Discussion
In this sub-cohort of critically ill septic patients from the prospective FINNAKI study we
found that the sCD73 levels were generally low at 0h compared to previously reported data,
showed a decrease to 24h, and an increase by day 5. Patients admitted with septic shock pre-
sented with the lowest concentrations. Moreover, patients with AKI and 90-day non-survivors
with severe sepsis presented with slightly higher levels compared to non-AKI patients and
90-day non-survivors, but the sCD73 levels were not independently associated with the devel-
opment of AKI or 90-day mortality.
The origin of sCD73 measured in plasma is thought to be mainly from shedding from blood
lymphocytes [20]. Compared to the values obtained in a population cohort using the same
analysis method, and previously measured in healthy volunteers and patients with acute pan-
creatitis with another method [12], the sCD73 levels in this cohort of critically ill patients were
low. A population cohort study has reported patients with peripheral arterial disease involving
chronic inflammation and hypoxia to present with increased CD73 activity [21]. We did not
find the sCD73 levels in patients with COPD or arteriosclerosis to be increased, but found
patients with chronic liver failure to have increased levels, likely because sCD73 levels have
been found to be confounded by elevated plasma alkaline phosphatase levels [21]. Regarding
the severity of critical illness, our findings corroborate results from patients with acute pancrea-
titis [12] in that patients with the most severe form of sepsis had the lowest sCD73 levels.
Majority of patients showed a decrease in sCD73 levels within the 24h in ICU. By day 5, we
demonstrated an increase in sCD73 levels. The drop seen at 24h could be due to increased deg-
radation of sCD73 or its leakage to the tissues. Unfortunately the lymphocyte levels were not
measured so that we cannot comment on whether the initial drop seen in sCD73 levels would
have been due to a reduction in circulating lymphocyte levels and decreased shedding of
sCD73. Patients categorized according to the magnitude of change in sCD73 levels between 0
and 24h did not differ regarding fluid balance, and, thus, the observeddrop is unlikely to be
due to hemodilution. Alternatively, CD73 productionmay be diminished like reported to
occur in leukocytes of patients with severe pancreatitis and low levels of sCD73 [12]. As CD73
dephosphorylates adenosine monophosphate into adenosine [6], our findings of a decrease in
sCD73 levels by 24h are partly in line with a study demonstrating that adenosine levels
decreased from the beginning of shock until 72h [22].
Patients with AKI presented with higher sCD73 levels at 0h and 24h. This is surprising, as
one could assume AKI to involve increased degradation of sCD73. Unfortunately, no studies
examining the sCD73 levels and AKI in the critically ill exist for comparison. Potentially,
endogenousmechanisms are working to increase the sCD73 levels given that work in mice has
shown induction of CD73 to be protective in ischemia-reperfusion–relatedAKI [10].
Decreasedplasma clearance of sCD73 in severe AKI might also explain the finding. The molec-
ular weight of sCD73 is about 70kDa [20], which exceeds the cut-off of modern filters used in
continuous RRT machines, and among patients with RRT sCD73 could accumulate. However,
no difference between the patients with and without RRT was observed except at 0h, when
RRT was not yet commenced. Finally, when adjusted for a number of confounders, the sCD73
levels at ICU admission were not independently associated with the development of AKI, indi-
cating that sCD73 is probably not useful in predicting the development of AKI.
We found the non-survivors with severe sepsis but not with septic shock to have higher
sCD73 levels compared to survivors. Patients with AKI also had higher sCD73 levels, which
could potentially also associate with worse outcome. However, the difference between survivors
and non-survivors regardless of the severity of sepsis was robust for exclusion of AKI patients,
suggesting that decreased clearance due to AKI or AKI per se do not explain these findings. If
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sCD73 levels in plasma are solely from circulating lymphocytes [20], then the increased levels
seen among the non-survivors could reflect a more pronounced response to infection and
potentially, also more severe infection. This, however, is unlikely, because patients with septic
shock had lower sCD73 levels. Overall, the differences between survivors and non-survivors
were small in magnitude, and were not independently associated with 90-day mortality after
adjusting for confounders. Therefore, sCD73 does not seem to be a useful general biomarker
for predictingmortality. Possibly, more frequent sampling would help to reveal whether there
are detectable short-term trends in the sCD73 levels that would further help to reveal the com-
plex pathophysiology behind these syndromes.
The encouraging results of using interferon-beta to increase the activity of CD73, and
potentially, decrease the permeability of pulmonary capillaries, showed that among patients
with ARDS the treatment increased the CD73 activity almost to three-fold during the dosing
period [13]. In a sub-analysis of the current analysis, we found that sCD73 levels correlated
with the activity of CD73 and the median baseline level of CD73 activity was higher compared
to the baseline of the ARDS cohort [13]. Albeit the non-survivors in our study with severe sep-
sis had higher sCD73 levels compared to survivors, the differences were generally very small
and not independently associated with an increased risk for mortality. Most notably, no differ-
ence in sCD73 among patients with septic shock was seen at any time-point. Therefore, our
results do not exclude the possibility that induction of CD73 could turn out to be useful also
among patients with septic shock in future studies as has been suggested for ARDS [13].
The strengths of our analysis include detailed collection of clinical data and the multicenter
design. Several limitations should be discussed, however. First, to study the trend in sCD73 lev-
els, we analyzed samples from patients of whom both 0h and 24h plasma were available. There-
fore, those who died or were discharged shortly after admission were excluded (9.8% of the
severe sepsis FINNAKI cohort) [2]. Inclusion of those with imminent death or very short ICU
stay indicating rapid improvement of clinical status would not have served the aims of this
study, however, as these subjects are unlikely to benefit from predictive biomarkers. Second,
analyzing samples with more frequent sampling might have helped to better detect the kinetics
of sCD73 regarding the development of septic shock. Third, we did not analyze samples from
non-septic controls, which might have helped us to separate the effects of critical illness as such
and infection per se. Fourth, the differences between all groups in the sCD73 concentrations
were generally small, and the clinical significance of these is unclear.
Conclusions
In conclusion, in this post-hoc laboratory analysis prospective, multicenter FINNAKI study
among septic critically ill patients, we found that the sCD73 levels were generally low and
showed a further decrease from 0h to 24h. Moreover, the sCD73 levels were higher in AKI ver-
sus non-AKI patients and in non-survivors with severe sepsis than in survivors, but were not
independently associated either with the development of AKI or 90-day mortality. The sCD73
levels do not seem useful in predicting the outcome of patients with severe sepsis or shock.
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